PenRad, provider of the leading mammography and lung analytics platforms, announces the addition of new products, bolstering clinic revenue through automation and electronic communication.
PenRad puts cancer risk assessment in the hands of the patient, maximizing engagement and satisfaction. “Identifying patients at high risk for breast cancer, genetic screening eligibility and advanced breast imaging has never been more straightforward and does not require additional staff,” says Greg Gustafson, PenRad’s President. PenRad’s High-Risk Breast Clinic module enhances client revenue, empowers patients, provides a market differentiator, and attracts generations to come.
The genetic testing eligibility algorithms compute eligibility based on 1st, 2nd, 3rd degree relatives with BRCA 1/2 and/or cancer histories of breast, colon, endometrial, NNN, ovarian, pancreatic, and prostate cancers. For Myriad Genetics clients, a complimentary interface securely transmits patient data and testing results to and from Myriad’s genetic counselors.
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs
Prior to a patient's appointment PenRad’s PenConnect sends a secure PenXpress link that enables them to refresh medical and risk history, automatically calculating their risk for developing breast cancer and genetic testing eligibility. The patient may complete their update in the clinic or their personal device from the comfort of their home. Gustafson adds, “empowering patients with a sense of ownership in their care and confidence in their journey, all the while streamlining intake for the clinic is a win-win for all.”
Visit PenRad at AHRA booth 423 in Nashville, August 1 – 4, personal risk analysis and demonstration available. Ask about increasing your clinic revenue by up to $20 per patient.